NOV 04, 2016 2:46 PM PDT

Scientists ID Key Protein in Ovarian Cancer's Growth

WRITTEN BY: Xuan Pham

Seeking to unravel the mysteries surrounding ovarian cancer development, researchers at the University of Michigan identified a protein that appears to be key to the cancer’s proliferation and migration.

Image credit: Pixabay.com 


The protein of interest is an epidermal growth factor protein, known as EGFL6. Proteins in this family are involved in cell growth, proliferation, and differentiation. As such, it is not hard to imagine a role for these rogue proteins in cancer development.
 
For ovarian cancer, researchers found that EGFL6 seemed to trigger cancer’s growth by 2 to 3 times the normal rate. In particular, this protein seemed to assert its effects on cancer stem cells, which can give rise to other cancer types. Of note, these types of cells are often more resistant to treatment.
 
The team found that EGFL6 spurred cancer stem cells to divide not only more often, but in an asymmetric fashion. That is, after division, the resulting daughter cells don’t have identical characteristics. This property increases the likelihood of further cancer mutations and cancer cell diversity, making it that much more difficult to treat.
 
"What this means is that the stem cell population remains stable. But the daughter cells, which can have a burst of growth, multiply and allow the cancer to grow," says Ronald J. Buckanovich, a professor of hematology/oncology and gynecologic oncology at the University of Michigan Medical School, and the study’s senior author.
 


In addition, the team found that along with abnormal growth and division, EGFL6 also made it more likely for cells to migrate. In the context of cancer, this means that the protein enables cancer cells to metastasize. Treatment of an antibody blocking EGFL6 in mice showed a significant reduction in cancer growth and metastasis – good news for treatment options in human ovarian cancer cases.
 
"The bigger implication is for women at high risk of ovarian cancer," he notes. "These patients could be treated before cancer develops, potentially blocking cancer from developing or preventing it from spreading. If cancer did develop, it could be diagnosed at an early stage, which would improve patient outcomes."
 
Ovarian cancers have one of the highest mortality rates, ranking fifth in cancer deaths among women. Of the 22,000 new estimated cases of ovarian cancer this year, only 10-15 percent of patients will be successfully treated. Thus, the team is hoping to produce a version of the EGFL6 antibody for humans, which is not yet available.

Additional source: University of Michigan Health System

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAR 18, 2020
Cancer
MAR 18, 2020
Statins could reduce heart damage from breast cancer treatment
Cancer treatments have a lot of side effects. For breast cancer chemotherapies that use drugs like anthracycline an ...
MAR 22, 2020
Cancer
MAR 22, 2020
What is "Shotgun ion mobility mass spectrometry sequencing"?
Research published recently in Nature Communications highlights a new method of mapping an essential family of polysacch ...
APR 09, 2020
Cancer
APR 09, 2020
The Unexpected Anti-Cancer Effects of the Human Telomerase
The research to find effective treatments and diagnosing tools in the fight against cancer has led to a thorough investi ...
APR 21, 2020
Clinical & Molecular DX
APR 21, 2020
Skin Deep: Handheld Device Sees the Earliest Signs of Cancer
Researchers have developed a handheld device that can image structures under the skin at resolutions 100 times greater t ...
MAY 09, 2020
Cancer
MAY 09, 2020
Disney movies boost quality of life during chemo
Have you considered popping in a Disney movie during your next chemotherapy session? A study published recently in JAMA ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
Loading Comments...